ALKS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alkermes Plc (ALKS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is currently oversold based on RSI, but the technical indicators suggest a bearish trend. The company's recent financial performance shows declining revenue and net income, which raises concerns about its growth potential. While analysts have a mixed view with some positive long-term prospects in its narcolepsy franchise, the lack of strong immediate catalysts and weak trading sentiment make it prudent to hold rather than buy at this time.
The stock is in a bearish trend with MACD negatively expanding and RSI at 17.159, indicating oversold conditions. Moving averages are converging, and the price is near the S1 support level of 28.717. The stock has a 30% chance of minor gains in the next day and moderate gains over the next month, but the current trend remains weak.
Analysts highlight potential growth in the company's narcolepsy franchise, particularly with Lumryz and alixorexant in late-stage development. Wolfe Research initiated coverage with an Outperform rating, indicating optimism about long-term prospects.
Recent financials show a YoY revenue decline of -10.57%, net income drop of -66.32%, and EPS decrease of -67.05%. The stock's price has dropped -3.18% in the regular market session, and there is no significant news or event-driven catalyst to support a rebound.
In Q4 2025, Alkermes reported a revenue decline to $384.55M (-10.57% YoY), net income dropped to $49.34M (-66.32% YoY), and EPS fell to $0.29 (-67.05% YoY). However, gross margin improved to 87.98% (+2.84% YoY), indicating cost efficiency.
Analysts have mixed views. H.C. Wainwright lowered its price target to $43 from $46, maintaining a Neutral rating. Wolfe Research initiated coverage with an Outperform rating and a $45 price target, citing potential in the narcolepsy franchise. BofA raised its price target to $34 from $33, reflecting optimism about the Avadel acquisition and orexin pricing.
